ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

SPC 2004

A development code.

Its studies are mostly in Essential Hypertension, led by Shin Poong Pharmaceutical.

Furthest: phase 2, since Feb 10, 20251 company-led study, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shin Poong Pharmaceutical11 open or runningphase 2since Feb 10, 2025Feb 10, 2025none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 10, 2025First study: phase 2 study in Essential HypertensionFirst studyNCT06826872 · 252 planned · Korea, Republic of

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06826872Essential Hypertension · Korea, Republic of2RecruitingOct 8, 2025252

How it is read

Names in the registry

  • “SPC 2004”, 1 entry

Codes read as this program: SPC2004.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.